

JAMES E. CLYBURN
CHAIRMAN
MAXINE WATERS
CAROLYN B. MALONEY
NYDIA M. VELÁZQUEZ
BILL FOSTER
JAMIE RASKIN
ANDY KIM

ONE HUNDRED SIXTEENTH CONGRESS
Congress of the United States
House of Representatives

STEVE SCALISE
RANKING MEMBER
JIM JORDAN
BLAINE LUETKEMEYER
JACKIE WALORSKI
MARK E. GREEN, M.D.

SELECT SUBCOMMITTEE ON THE CORONAVIRUS CRISIS
2157 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6143

PHONE (202) 225-4400

<https://coronavirus.house.gov>

July 16, 2020

Rear Admiral John Polowczyk
Supply Chain Stabilization Task Force
Vice Director of Logistics, J4
Joint Chiefs of Staff
Department of Defense
1000 Defense Pentagon
Washington, D.C. 20301


Dear Rear Admiral Polowczyk:

Enclosed are post-hearing questions that have been directed to you and submitted to the official record for the Select Subcommittee on the Coronavirus Crisis hearing on “The Administration’s Efforts to Procure, Stockpile, and Distribute Critical Supplies” held on Thursday, July 2, 2020.

In order to ensure a complete hearing record, please return your written response to the Subcommittee by Thursday, July 30, 2020, including each question in full as well as the name of the Member. Your response should be addressed to the Subcommittee office at 2157 Rayburn House Office Building, Washington, D.C. 20515. Please also send an electronic version of your response by email to Senam Okpattah, at Staff Assistant, Senam.Okpattah@mail.house.gov.

Thank you for your prompt attention to this request. If you need additional information or have any questions, please contact Subcommittee staff at (202) 225-5051.

Sincerely,


James E. Clyburn
Chairman

cc: The Honorable Steve Scalise, Ranking Member

Questions for Rear Admiral John Polowczyk
Supply Chain Stabilization Task Force
Vice Director of Logistics, J4
Joint Chiefs of Staff
Department of Defense
Questions from Congressman Raskin

Thursday, July 2, 2020, Hearing: “The Administration’s Efforts to Procure, Stockpile, and Distribute Critical Supplies”

1. How do efforts to replenish the Strategic National Stockpile (SNS) differ from those designated for direct distribution? Please provide an overview of the breakdown between these various efforts, including what percentage of procurements are designated for the SNS.
2. To ensure the correct supplies of PPE are, in fact, getting to the right places at the right time, is FEMA actively tracking the delivery of PPE as it is disseminated to states, municipalities, and hospitals?
3. Do you know what amount of PPE ultimately reaches hospitals even when first delivered at the state or local level? If so, please provide that data to the Subcommittee. If not, does the Administration have the requisite authority to compel this level of reporting for the PPE it delivers at the state, local, and hospital levels, including the use of DPA?
4. Where is the U.S. currently obtaining PPE and testing supplies? Please provide source information by company and place of origin including items imported and domestically produced.
5. What is the overall supply chain health of PPE and testing supplies from a global standpoint? What is the production capacity of the private sector, and what percentage of this is available for the U.S. to procure without being locked out from competition with other markets?

**Questions for Rear Admiral John Polowczyk
Supply Chain Stabilization Task Force
Vice Director of Logistics, J4
Joint Chiefs of Staff
Department of Defense
Questions from Congressman Kim**

Thursday, July 2, 2020, Hearing: “The Administration’s Efforts to Procure, Stockpile, and Distribute Critical Supplies”

1. What efforts does the Task Force make to track current and projected needs for PPE and other critical supplies across the country? Please describe how often these projections are updated, what inputs and assumption are used to determine them, which populations the projections account for (i.e., health care workers, other front-line workers, etc.), and any breakdown of projected need by state or other locality.
2. Does the country currently have enough PPE to deal with the potential for an exponential increase in coronavirus cases, and all of the hospitalizations that will go with that?
3. What steps is FEMA taking to ensure information is gathered on the purchase and current supply of critically needed PPE at the state, local, and hospital level? Does the Administration have the necessary authority—including the use of the DPA—to compel the release of this information from state and local governments and hospitals, especially if they are not “forthcoming”?
4. Please describe all efforts to purchase PPE and testing supplies in bulk and to negotiate better prices and faster delivery than would be available to multiple purchasers making smaller orders?
5. Does the U.S. have the capacity, or could it develop the capacity, to manufacture more PPE, testing materials, and medical supplies? How much is the domestic private sector able to produce beyond its current output, and what are the barriers currently preventing this production?
6. Will shortages of raw materials be a barrier to sourcing or manufacturing PPE, and if so, what is the Administration doing to address this issue?